News

Acrivon Therapeutics Unveils Key Data at Two Major Conferences

Acrivon Therapeutics Unveils Key Data at Two Major Conferences

Acrivon Therapeutics Showcases AP3 Platform at Leading Conferences

Acrivon Therapeutics, Inc. is set to demonstrate its innovative AP3 platform at two prominent scientific conferences within the upcoming days. This promising platform plays a pivotal role in the streamlined drug discovery and clinical advancement, particularly for its leading candidates, ACR-368 and ACR-2316.

Understanding the AP3 Platform

The Acrivon Predictive Precision Proteomics (AP3) platform represents a sophisticated approach in precision medicine aimed at identifying clinical biomarkers. This capability has been crucial for ACR-368, which is entering a Phase 2b study. The OncoSignature assay developed through AP3 has shown statistically significant results in validating patient responses. ACR-2316, also enabled by the AP3 compilation, demonstrates remarkable potential as a WEE1/PKMYT1 inhibitor with superior activity observed in initial studies.

Importance of Upcoming Presentations

At the Human Proteome Organization (HUPO) World Congress and the EORTC-NCI-AACR Symposium, Acrivon scientists will share their findings, highlighting how AP3 empowers clinical development. According to Kristina Masson, Ph.D., Acrivon’s dedication to harnessing cutting-edge technology has led to compelling discoveries that aid in overcoming challenges in biomarker discovery and tumor treatment resistance.

Details of Presentations

The following details outline the upcoming presentations at the HUPO 2024 World Congress:

  • Title: Acrivon Predictive Precision Proteomics (AP3)-guided development and prospective clinical registrational-intent Phase 2 validation of the response-predictive OncoSignature test for ACR-368
  • Session: Clinical Proteomics I
  • Session Date and Time: Presentation scheduled for October 21, from 1:15 p.m. – 3:15 p.m. CEST
  • Poster ID Number: P-I-0346
  • Abstract Number: 525

Additionally, the ACR-2316 presentation is scheduled as follows:

  • Title: ACR-2316: a potent, selective WEE1/PKMYT1 inhibitor rationally designed for superior single agent activity using Acrivon Predictive Precision Proteomics (AP3)
  • Session: Clinical Proteomics II
  • Session Date and Time: October 22, from 1:00 p.m. – 3:00 p.m. CEST
  • Poster ID Number: P-II-0624
  • Abstract Number: 513

ENA 2024 Symposium Presentation Features

At the ENA 2024 Symposium, Acrivon will also present details about ACR-2316:

  • Title: Rational design of ACR-2316, a novel, potent WEE1/PKMYT1 inhibitor with superior single agent activity using Acrivon Predictive Precision Proteomics (AP3)
  • Session Title: DNA Repair Modulation
  • Session Date and Time: October 25, from 9:00 a.m. – 3:00 p.m. CEST
  • Poster Board Number: PB318

Acrivon’s Commitment to Innovation

Acrivon Therapeutics is focused on developing precision oncology treatments tailored to individual patient profiles. Their proprietary platform, AP3, enables the measurement of compound-specific actions on tumor signaling and resistance mechanisms. This technology not only optimizes drug development but also assists in identifying patients best suited for these therapies.

Currently, Acrivon is advancing ACR-368, a selective small molecule inhibitor aimed at CHK1 and CHK2, currently in a potentially registrational Phase 2 trial for various tumors. The company has gained Fast Track designation from the FDA, which marks a significant milestone in its ongoing clinical journey. Results from recent studies highlight a confirmed overall response rate and compelling data on patient selection based on the OncoSignature test.

Looking Ahead

As Acrivon continues navigating the complexities of drug development, the outcomes and insights gleaned from its advanced presentations are expected to be instrumental in fostering innovation within the biopharmaceutical industry. The unique applications of the AP3 platform signal exciting possibilities not only for Acrivon’s therapies but also for the future of personalized medicine.

Frequently Asked Questions

What is the AP3 platform used for?

The AP3 platform is used for drug discovery and clinical development, helping identify biomarkers and optimize treatment designs.

When will the presentations take place?

The presentations will occur on October 21 and 22, 2024, at the HUPO World Congress and on October 25, 2024, at the ENA 2024 Symposium.

What are the key candidates being discussed?

The candidates discussed include ACR-368 and ACR-2316, two innovative treatments in cancer therapy.

What achievements has Acrivon made with ACR-368?

Acrivon has gained Fast Track designation from the FDA and has reported positive clinical data in its trials for ovarian and endometrial cancer.

How does Acrivon help tailor treatments for patients?

Acrivon utilizes its proprietary AP3 platform to match patients to treatments based on predicted sensitivity, enhancing personalized medicine approaches.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Wulcea Pioneers Safety in Smart Heated Apparel

Updated Category News Views 71

Tech Behind the Warmth and Safety You ever turn on a heated jacket and wonder if it'll keep you safe as much as warm? That's the scene with Wulcea, a brand diving headfirst into the smart heated clothing market. People are waking up to what’s inside these technological coats, not just how they feel on a frosty walk. It’s the kind of scenario where safety meets...

Continue Reading
DKS Lawsuit Deadline: Investors Must Act by Nov 3, 2026

Updated Category News Views 109

Clock's Ticking for DICK'S Investors If you've got money tied up in DICK'S Sporting Goods—bought between September 8, 2025, and August 24, 2026—listen up. There's a class action lawsuit aiming to recover some of what might've slipped through your fingers. Come November 3, 2026, the door slams shut on your chance to get involved. What's the Beef? Apparently, DICK'S had...

Continue Reading
Fluence Energy Faces Class Action: Investors Beware

Updated Category News Views 191

Storm Clouds Over Fluence Energy I'll tell you, I ain't surprised when companies face the music for dressing up their books. Fluence Energy, Inc. (NASDAQ: FLNC)—those wallopers are now caught in a legal maelstrom with a securities fraud class action lawsuit hanging over their heads. It's hard to feel sorry for 'em when the writing's on the wall. Allegations and...

Continue Reading
SKYWORTH Solar's Solavita: Energizing Global Microgrids

Updated Category News Views 150

Aiming for Global Reach with Solavita Usually, when a company flings a new brand into the arena, you're looking at a whole bunch of promises and probably a fat folder of paperwork you don't want to read. But when SKYWORTH Solar dishes out Solavita as its new ace in the smart microgrid game, you reckon there's a bit of serious starch in the collar. Harnessing Worldwide...

Continue Reading
HanAll F&B Pioneers New Path for Domestic Rice Noodles

Updated Category News Views 263

New Spin on an Old Favorite: Rice Noodles Forget about the same old wheat noodles clogging up the pantry. HanAll F&B is revamping the noodle game with a homegrown twist, setting sights on a future where Korean rice isn't just for steaming, soup, or sushi. This outfit from Taebaek, Gangwon, has got its hands deep in the rice flour, finessing a patent that aims to make...

Continue Reading
OlloBot's Emotional AI Robots Connect Beyond Tasks

Updated Category News Views 87

OlloBot Eyes Emotional Bonds, Not Just Robotics Power Is it just me, or is OlloBot onto something deep with their emotional AI companions? They've set a course that might just redefine how we perceive home robotics. At IFA Berlin 2026, they didn't just strut their technical stuff. Nope, they took it beyond gears and gadgets, turning heads with a robot that does more than...

Continue Reading
NABEP's Strategic Push: 41 Rigs to Bolster Output

Updated Category News Views 213

On The Ground: NABEP's Expanding Venezuelan Presence Think of oil production as a high-stakes poker game where each drill and rig is a well-placed bet. North American Blue Energy Partners (NABEP) is going all in on Venezuela, boosting their rig fleet and pushing production capacity to new heights. Set your sights on November when NABEP's in-country fleet will hit 41 rigs...

Continue Reading
UBCF Strikes Big in Times Square with New Billboards

Updated Category News Views 142

From the Shadows to the Spotlight Ever seen someone step up to the plate and knock it out of the park? That's what the United Breast Cancer Foundation (UBCF) is doing by plastering their mission right across Times Square. Talk about grabbing the bull by the horns, eh? With not one, but two billboards now gracing one of the globe's most iconic public spaces, they've...

Continue Reading
Langford Chosen for Navy Mutual's 2026 Bolles Award

Updated Category News Views 332

Awarding a Military Financial Educator There's something profoundly rewarding when hard work and dedication get their due recognition. That's precisely what's happened for Lacey Langford, who’s just been awarded the Lieutenant Timothy Dix Bolles Excellency in Education Award by the Navy Mutual Aid Association, or simply Navy Mutual. This isn’t just some...

Continue Reading
BAIC FOTON Eyes Africa for Bold Expansion Moves

Updated Category News Views 179

Pushing the Pedal to the Metal in Africa So here's the thing. When a company like BAIC FOTON sets its sights on Africa, you best believe they're not just twiddling their thumbs. Coming off a strong streak in the commercial vehicle game—topping China's sales for 21 years and exports for 15—their ambitions are now married to a keen interest in Africa's burgeoning...

Continue Reading

Top 5 Most Recently Viewed Articles

Baxter International Faces Stock Decline Amid Outlook Revisions

Updated Category News Views 177

Baxter International Inc. Stock Performance Baxter International Inc. (NYSE: BAX) is currently facing challenges as its stock recently hit a 52-week low. This significant drop is attributed to the company’s latest revision of its annual financial outlook. Third Quarter Results In its third quarter, Baxter reported an adjusted earnings per share (EPS) of 69 cents, which...

Continue Reading
GLMX Sees Remarkable Growth in Third Quarter 2024

Updated Category News Views 133

GLMX Reports Significant Third Quarter Growth GLMX, known for its innovative technology solutions in securities financing, recently released details about its impressive performance in the third quarter of 2024. The company has established itself as a frontrunner in transforming the landscape of money markets and total return swaps, and this quarter marked a distinctive...

Continue Reading
Zuora to Be Acquired by Silver Lake and GIC for $1.7 Billion

Updated Category News Views 665

Zuora's Major Acquisition Announcement Zuora, Inc. (NYSE: ZUO), a renowned provider of monetization solutions tailored for today’s evolving business models, has made headlines with its recent announcement of a definitive agreement to be acquired by Silver Lake, a premier global technology investment firm, along with GIC Pte. Ltd., a leading investment firm. This...

Continue Reading
Borregaard ASA Announces Convertible Loan Initiative with Alginor

Updated Category News Views 156

Borregaard ASA Engages in Convertible Loan for Alginor Borregaard ASA is set to collaborate with Must Invest and Hatteland Group as guarantors for a substantial NOK 200 million convertible loan aimed at supporting Alginor's growth. Details of the Convertible Loan This strategic loan allows for conversion into new shares by the lenders at a subscription price of NOK 10 per...

Continue Reading
Legal Action Opportunities for Venture Global, Inc. Investors

Updated Category News Views 171

Advancements and Challenges Facing Venture Global, Inc. Venture Global, Inc. (NYSE: VU) is taking significant steps in the liquified natural gas sector while facing scrutiny from investors. The company has gained attention for its unique approach to bringing liquified natural gas (LNG) to the global market efficiently. It’s essential for investors to be aware of any...

Continue Reading